Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Integra LifeSciences makes medical devices and tissue-based products used in brain surgery, orthopedic care, and wound healing.
Integra LifeSciences is a medical device company that makes the tools and materials surgeons use in some of the most delicate parts of the body. Its two big areas are neurosurgery β things like brain and spine surgery β and orthopedic devices, plus specialized tissue products used to help wounds heal. Hospitals and clinicians around the world buy these products, and they tend to be chosen by surgeons who want reliable, specialized gear rather than the cheapest option.
The company's roots are in one genuinely clever idea: making a synthetic substitute for human skin. Its founders developed an artificial skin product for burn victims, which later evolved into a broader tissue-regeneration business. That's the "regenerative tissue technologies" side of the company today β products derived from human tissue and other materials that help the body repair itself, used in wound care and reconstructive surgery. The other half of the business is the more workmanlike stuff: surgical instruments and implants, especially the hardware neurosurgeons use when they open up a skull or stabilize a spine. The business is built on a simple reality of medicine. Surgeon preferences are sticky β once a doctor trains on and trusts a particular instrument, they keep asking for it β and hospital buying committees are hard to win but hard to lose. That gives Integra steady, recurring revenue with decent margins. But it's a crowded field, competing with giants like Medtronic and Stryker, and the company has had a rough stretch: quality and regulatory problems at one of its manufacturing plants forced a recall and a temporary halt on shipping certain products, which hit sales and the stock price. That plant issue is the key thing to watch β fixing manufacturing quality is the difference between the business humming along and bleeding credibility with regulators and hospitals.
Integra doesn't pay a dividend and isn't a flashy growth story; it plows cash into developing new products and buying smaller companies to bolt on new technologies. The bet is that steady demand for surgery, an aging population, and sticky surgeon relationships keep the machine running. The risk is that when your product goes inside someone's brain, a manufacturing mistake isn't just a bad quarter β it's a trust problem that takes a long time to repair.
Saved answer Β· last researched 16 Nov 2026